Cargando…

The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review

SIMPLE SUMMARY: Despite the implementation of specific dose constraints on healthy tissues to maintain the theoretical risk of late toxicity below 5% five years after radiotherapy (RT), many patients experience “unusual” toxicity during their oncological follow-up. This narrative review describes th...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Sandrine, Orlandi, Ester, Deneuve, Sophie, Barcellini, Amelia, Chalaszczyk, Agnieszka, Behm-Ansmant, Isabelle, Hettal, Liza, Rancati, Tiziana, Vogin, Guillaume, Thariat, Juliette
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776433/
https://www.ncbi.nlm.nih.gov/pubmed/36551737
http://dx.doi.org/10.3390/cancers14246252
_version_ 1784855864327274496
author Pereira, Sandrine
Orlandi, Ester
Deneuve, Sophie
Barcellini, Amelia
Chalaszczyk, Agnieszka
Behm-Ansmant, Isabelle
Hettal, Liza
Rancati, Tiziana
Vogin, Guillaume
Thariat, Juliette
author_facet Pereira, Sandrine
Orlandi, Ester
Deneuve, Sophie
Barcellini, Amelia
Chalaszczyk, Agnieszka
Behm-Ansmant, Isabelle
Hettal, Liza
Rancati, Tiziana
Vogin, Guillaume
Thariat, Juliette
author_sort Pereira, Sandrine
collection PubMed
description SIMPLE SUMMARY: Despite the implementation of specific dose constraints on healthy tissues to maintain the theoretical risk of late toxicity below 5% five years after radiotherapy (RT), many patients experience “unusual” toxicity during their oncological follow-up. This narrative review describes the methods of individual radiation sensitivity (iRS) diagnosis, their impact on the RT workflow as well as initiatives to support clinical decision-making initiatives. ABSTRACT: (1) Background: radiotherapy is a cornerstone of cancer treatment. When delivering a tumoricidal dose, the risk of severe late toxicities is usually kept below 5% using dose-volume constraints. However, individual radiation sensitivity (iRS) is responsible (with other technical factors) for unexpected toxicities after exposure to a dose that induces no toxicity in the general population. Diagnosing iRS before radiotherapy could avoid unnecessary toxicities in patients with a grossly normal phenotype. Thus, we reviewed iRS diagnostic data and their impact on decision-making processes and the RT workflow; (2) Methods: following a description of radiation toxicities, we conducted a critical review of the current state of the knowledge on individual determinants of cellular/tissue radiation; (3) Results: tremendous advances in technology now allow minimally-invasive genomic, epigenetic and functional testing and a better understanding of iRS. Ongoing large translational studies implement various tests and enriched NTCP models designed to improve the prediction of toxicities. iRS testing could better support informed radiotherapy decisions for individuals with a normal phenotype who experience unusual toxicities. Ethics of medical decisions with an accurate prediction of personalized radiotherapy’s risk/benefits and its health economics impact are at stake; (4) Conclusions: iRS testing represents a critical unmet need to design personalized radiotherapy protocols relying on extended NTCP models integrating iRS.
format Online
Article
Text
id pubmed-9776433
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97764332022-12-23 The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review Pereira, Sandrine Orlandi, Ester Deneuve, Sophie Barcellini, Amelia Chalaszczyk, Agnieszka Behm-Ansmant, Isabelle Hettal, Liza Rancati, Tiziana Vogin, Guillaume Thariat, Juliette Cancers (Basel) Review SIMPLE SUMMARY: Despite the implementation of specific dose constraints on healthy tissues to maintain the theoretical risk of late toxicity below 5% five years after radiotherapy (RT), many patients experience “unusual” toxicity during their oncological follow-up. This narrative review describes the methods of individual radiation sensitivity (iRS) diagnosis, their impact on the RT workflow as well as initiatives to support clinical decision-making initiatives. ABSTRACT: (1) Background: radiotherapy is a cornerstone of cancer treatment. When delivering a tumoricidal dose, the risk of severe late toxicities is usually kept below 5% using dose-volume constraints. However, individual radiation sensitivity (iRS) is responsible (with other technical factors) for unexpected toxicities after exposure to a dose that induces no toxicity in the general population. Diagnosing iRS before radiotherapy could avoid unnecessary toxicities in patients with a grossly normal phenotype. Thus, we reviewed iRS diagnostic data and their impact on decision-making processes and the RT workflow; (2) Methods: following a description of radiation toxicities, we conducted a critical review of the current state of the knowledge on individual determinants of cellular/tissue radiation; (3) Results: tremendous advances in technology now allow minimally-invasive genomic, epigenetic and functional testing and a better understanding of iRS. Ongoing large translational studies implement various tests and enriched NTCP models designed to improve the prediction of toxicities. iRS testing could better support informed radiotherapy decisions for individuals with a normal phenotype who experience unusual toxicities. Ethics of medical decisions with an accurate prediction of personalized radiotherapy’s risk/benefits and its health economics impact are at stake; (4) Conclusions: iRS testing represents a critical unmet need to design personalized radiotherapy protocols relying on extended NTCP models integrating iRS. MDPI 2022-12-19 /pmc/articles/PMC9776433/ /pubmed/36551737 http://dx.doi.org/10.3390/cancers14246252 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Pereira, Sandrine
Orlandi, Ester
Deneuve, Sophie
Barcellini, Amelia
Chalaszczyk, Agnieszka
Behm-Ansmant, Isabelle
Hettal, Liza
Rancati, Tiziana
Vogin, Guillaume
Thariat, Juliette
The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
title The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
title_full The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
title_fullStr The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
title_full_unstemmed The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
title_short The Normal, the Radiosensitive, and the Ataxic in the Era of Precision Radiotherapy: A Narrative Review
title_sort normal, the radiosensitive, and the ataxic in the era of precision radiotherapy: a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776433/
https://www.ncbi.nlm.nih.gov/pubmed/36551737
http://dx.doi.org/10.3390/cancers14246252
work_keys_str_mv AT pereirasandrine thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT orlandiester thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT deneuvesophie thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT barcelliniamelia thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT chalaszczykagnieszka thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT behmansmantisabelle thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT hettalliza thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT rancatitiziana thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT voginguillaume thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT thariatjuliette thenormaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT pereirasandrine normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT orlandiester normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT deneuvesophie normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT barcelliniamelia normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT chalaszczykagnieszka normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT behmansmantisabelle normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT hettalliza normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT rancatitiziana normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT voginguillaume normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview
AT thariatjuliette normaltheradiosensitiveandtheataxicintheeraofprecisionradiotherapyanarrativereview